Company intelligence / Profile preview

Ibiome Biology

Hefei, Anhui Sheng, China

Ownership: Private
Development stage: Other

Overview

Ibiome Biology is a China-based biotech company focused on innovative research and development of human gut microbiota for therapeutic purposes. The company has several programs in clinical and preclinical stages targeting metabolic, immune, neurological, and oncological diseases using gut microbiota-based therapies, small molecules, and vaccines. Its lead assets are in clinical trials for obesity, inflammatory bowel disease, recurrent colon cancer (targeting PD-1), and depressive disorder.

Therapeutic areas: PsychiatryGastroenterologyEndocrinologyOncology
Modalities: Live biotherapeutic product therapy (gut microbiota-based therapies)Small moleculeTherapeutic vaccine
Industry: Biotech

Partnerships

not publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Ibiome Biology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ibiome Biology.

Explore the full profile